This session will explore strategies for ensuring vaccine security and self-reliance at both national and regional levels. It will highlight the importance of building robust vaccine production capacities, strengthen supply chains, and enhance local manufacturing to reduce dependency on external sources. Discussions will also focus on fostering regional collaborations, improving access to vaccines, and addressing challenges in immunization distribution. As the world continues to navigate health crises, the session will emphasize the need for sustainable vaccine solutions to ensure long-term public health resilience and self-sufficiency.

• Cross-Border Collaboration for Innovation: How partnerships between governments and stakeholders are driving vaccine development in the region
• Equitable Access to Vaccines: Addressing the challenges of ensuring vaccines reach underserved populations
• Efficient Budget Management: The role of strategic budget allocation in supporting vaccine programs
• Challenges in New Vaccine Rollouts: Overcoming hurdles in the launch of new vaccines in SEA

• What are the challenges in the current malaria vaccines?
• Why is novel malaria vaccine candidate needed?
• Why wheat germ cell-free protein synthesis system?
• Post-genome blood-stage malaria vaccine candidate discovery

• Challenges and Tools for Plasmodium vivax vaccine development
• Protein VS mRNA vaccines for Plasmodium vivax
• Progress on mRNA vaccine development of Plasmodium vivax
• Next steps: challenges and potential solutions

• Background information on circ-RNA and potential upsides
• Design of nipah mRNA vaccine candidate
• Overview of preclinical data to-date
• Next steps and circ-RNA platform feasibility

• Ultracentrifugation, a scalable automated technology
• Ultracentrifugation versus Filtration and Chromatography
• Separation flexibility and versatility
• Sample integrity and cross contamination prevention

• Accelerating clinical trial timelines through adaptive designs and streamlined processes
• Ensuring diversity in trial populations to reflect Southeast Asia’s demographic variability
• Strengthening infrastructure and collaboration across countries to support trial execution
• Overcoming regional regulatory challenges to enhance trial efficiency and accessibility

• The foundational role of secure digital platforms in modern, data-intensive clinical trials.
• ⁠Illustrating concrete risks to trial integrity and patient data, such as using outdated server components with known vulnerabilities (e.g., CVE-2023-44487) and failing to encrypt communications over HTTP.
• The danger of security misconfigurations, such as missing critical HTTP headers (e.g., Content-Security-Policy, Referrer-Policy), that can expose trials to data leakage and attacks.
• How insecure digital platforms threaten compliance with the region's strict data privacy laws, such as Malaysia's and Thailand's PDPA, which mandate protection for sensitive health data.
• A call to action for implementing a proactive security posture—including robust access controls, regular vulnerability scanning, and secure development practices—as a non-negotiable prerequisite for building trust with patients, regulators, and partners.

• The shift from traditional to adaptive clinical trial designs: benefits in speed and cost reduction
• Leveraging flexibility in trial designs to accelerate decision-making and drug development
• Evolving regulatory frameworks in SEA that support adaptive trial methodologies
• Exploring how adaptive designs are opening up new research and market opportunities in the region

• Best practices for transitioning from lab-scale production to commercial manufacturing.
• Addressing challenges in scaling up bioprocessing and formulation.
• Ensuring consistency and quality control during the scale-up process.
• Implementing real-time monitoring systems to maintain product integrity during tech transfer.

• Creating stable vaccine formulations suitable for various environmental conditions
• The impact of adjuvants on boosting vaccine potency
• Addressing challenges in scaling up complex vaccine formulations
• Approaches to accelerate the vaccine formulation development process

• Update on mRNA platform development in Africa
• Pipeline of mRNA vaccine development for LMIC burden of diseases
• Partnerships to improve mRNA vaccine properties and freedom to operate
• Innovative approaches to mRNA technology transfer models for LMICs

• Safety and Efficacy Features of Respiratory-Delivered Vaccines: Examine the differences between injectable and inhalable vaccines in terms of effectiveness in stimulating mucosal immune response
• Innovative Methods for Vaccine Delivery to the Upper Respiratory Track: Introduce technologies such as nanoparticles, aerosol systems, and nasal sprays that can enhance precision in vaccine delivery.
• Challenges in Manufacturing and Evaluating New Vaccines: Analyze the difficulties associated with developing and approving respiratory vaccines, including formulation stability, clinical trials, and healthcare adoption.
• Future of Respiratory Vaccines and Their Impact on Public Health: Explore the potential of RNA-based vaccines, bioengineered vaccine carriers, and their role in global immunization programs.

• Rationale and Evolution of Leptospirosis Vaccine Development: Unmet needs and limitations of current vaccines
• Antigen Selection and Vaccine Design: Identification of key Leptospira antigens and vaccine targets
• Preclinical Testing in Animal Models: Mouse model: immunogenicity Hamster model: immunogenicity and protective efficacy
• Advancing the mRNA Vaccine Platform: Construct design, codon optimization, and LNP delivery – early development phase

• Novel Delivery System
• Immunogenicity
• Lyophilization
• Stability

• Innovation Frontiers in Preventive Vaccines
• Equity and Access Beyond Boundaries
• Trust, Misinformation, and Community Engagement
• Global Health Leadership for the Future of Immunization

• The rising burden of vaccine-preventable diseases in aging populations
• Making innovation matter: how to move from vaccine development to real-world protection
• Policy frameworks that support adult immunization
• Ensuring access: equity in procurement, financing, and public acceptance
• The role of cross-sector collaboration in shaping sustainable adult immunization programs

• The Role of Real-World Evidence (RWE) and Its Methodological Limitations
• The Potential and Strengths of RWE in Vaccine Evaluation
• Overcoming Limitations and Harnessing the Strengths of Real-World Data by Combining It with RCTs
• Introducing a Real-World Randomized Clinical Trial: FLUNITY-HD and What the Results Tell Us

• Halal certification – why and if this doable?
• Halal Vaccine Standards and Certification: Guidelines and processes for ensuring Halal compliance without compromising efficacy, safety and quality.
• Halal Aspects of vaccine materials and manufacturing requirements
• Halal certification

• Strategies for improving vaccine delivery in low- and middle-income countries
• Policy interventions to increase global vaccination rates
• The role of international organizations in enhancing vaccine equity
• Innovative approaches to ensure timely and effective vaccine distribution